myotonic dystrophy

Novartis muscle disease drug fails, capping third trial setback in a week

Novartis disclosed Tuesday that its experimental drug del-desiran failed to outperform placebo in a pivotal study for the rare muscle-wasting disease myotonic dystrophy type 1, marking the company's third clinical trial setback in roughly a week.